Fig 1: Human ILC2 have fused and polarized mitochondria.a, ILC2 Gating strategy Live CD45+ CD7+ Lin- CD94- NKG2A- CD56- CD16- CD127+ CRTh2+ (ILC2) and Live CD45+ CD7+ Lin- CD94+ CD16+ (NKDim). b, Percentage of ILC2 and NKDim in live CD45+ cells. c, FACS measurement of TMRM and MitoTracker in healthy donors of fresh ILC2 and NKDim (n = 12). d, Confocal microscopy in fresh ILC2 and NKDim (n = 7). e, MitoTracker and TMRM intensity (SD/Mean). f, ATP and ADP intensities quantified by label-free mass spectrometry in freshly sorted ILC2 and NKDim cells (n = 3). a-b, Data representative of 10 independent experiments with 2 to 4 donors each. c, Data from 12 healthy donors from at least 5 independent experiments. d-e, Data representative of 2 independent experiments with at least 3 donors. Dots are single cells in the analyzed field. Scale bar 5μm. f, Each dot represents a donor. A minimum of 2 technical replicates were analyzed per run. b, e, f, Floating bars indicate the mean, minimum and maximum values within the dataset. Statistics were assessed by two tailed t-test (b,e,f), not significant (ns), p > 0.05; **p < 0.01; ****p < 0.0001. Source data